| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2002;40:186.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Departments of Medicine and Radiology, Brigham and Womens Hospital and Harvard Medical School, Boston, Mass.
Correspondence to Deborah A. Price, MD, 221 Longwood Ave, Boston, MA 02115. E-mail daprice{at}partners.org
| Abstract |
|---|
|
|
|---|
Key Words: sodium blacks kidney renal circulation renin-angiotensin system
| Introduction |
|---|
|
|
|---|
Because salt intake is a major determinant of not only the state of the RAS but also the contribution of renin activity to renal vascular tone and renal perfusion, in this study we undertook to assess systematically the renal vascular response to a change in salt intake in healthy blacks. We also investigated the renal hemodynamic response to exogenously administered Ang II and the ACE inhibitor captopril in the low salt state when endogenous Ang II levels are high. In other settings, activation of the intrarenal RAS is associated with blunting of the renal hemodynamic response to changes in salt intake.2,3 Thus, a limited renal hemodynamic response to a change in salt intake would provide additional evidence favoring activation of the intrarenal RAS. The nature of the differential control in blacks and whites is also unclear. If the difference in renal perfusion is just as large on a low and high salt diet, the conclusion would be that a substantial shift in the entire relation exists. Conversely, if the renal hemodynamics are similar on a low salt diet but become different with an increase in salt intake, the difference in control mechanism would involve the processes responsible for suppression of the renin system on a high salt diet. In low salt balance, blunting of the renal response to Ang II and vasodilation to captopril is the normal state.4,5 We sought to determine if the level of blunting with Ang II or the dilation with captopril would be comparable in the 2 groups, as it was not on a high salt intake. Our data suggest that the difference between blacks and whites involves the ability of a high salt intake to suppress the intrarenal RAS, which corrects with an ACE inhibitor. This anomaly is similar to what we described in the control of renal perfusion and function in patients with type 2 diabetes mellitus5,6 and in some patients with essential hypertension.2,7 These observations provide further insight into the increased risk of nephropathy in blacks.
| Methods |
|---|
|
|
|---|
Subjects were studied twice, under both HS and LS balance, in random order. When the HS protocol was done first, subjects were placed on an HS diet (200 mmol of sodium, 100 mmol potassium, 2500 mL fluid intake per day) 3 days before admission. Each subject was admitted 24 to 48 hours before the study day and was maintained on the diet. Daily 24-hour urine collections were obtained for measurement of sodium, potassium, protein, and creatinine excretion. Subjects were studied when 24-hour urine sodium was >150 mmol/L. When the LS protocol was done first, subjects started an outpatient diet consisting of 10 mmol/L sodium, 100 mmol/L potassium, and at least 2500 mL fluid intake 3 to 4 days before admission. Each subject was admitted 3 to 4 days before the study day and maintained on the diet. Once the 24-hour urine sodium was <20 mmol/L, the study was initiated. While in LS balance, 11 blacks (age, 32±5 years) and 12 whites (age, 32±5 years) received 3 ng/kg per minute of Ang II for 45 minutes. Ang II was then discontinued. Captopril (25 mg) was administered orally; measurements for para-aminohippurate (PAH) and inulin were continued for an additional 135 minutes.
Protocol Sequence
Subjects fasted overnight and remained recumbent throughout the study. Studies began at
7 AM. One intravenous catheter was placed in each arm at least 2 hours before the study, one for infusions and the other for blood drawing. PAH and inulin were infused, and clearances reflected renal plasma flow (RPF) a glomerular filtration rate (GFR), respectively, as described previously.8 Blood samples for baseline PAH and inulin and PRA measurements were drawn 60 minutes later. Blood pressure was recorded by an automatic recording device (Dinamap, Critikon) at 15-minute intervals. During the Ang II infusion, blood pressure monitoring was recorded every 2 minutes.
Laboratory Procedures
Blood samples were collected on ice and spun immediately, and the plasma was stored at -80°C until the time of assay. Serum and urinary sodium and potassium levels were measured using the ion-selective electrode. Serum creatinine, PAH, and inulin were measured by an autoanalyzer technique. PRA was measured by radioimmunoassay.9
Statistical Analysis
All data are expressed as mean±SEM. Statistical differences in 2-sample data were assessed by t test and the nonparametric Mann-Whitney test. Analysis of data within each group was done by paired t tests. The null hypothesis was rejected when the probability value was <0.05.
| Results |
|---|
|
|
|---|
|
|
PRA was not statistically different between blacks and whites on either diet (Table 2). RPF was lower in healthy blacks compared with age-matched whites while in balance on an HS diet (575±24 versus 636±20 mL/min per 1.73 m2; P=0.033, Table 3). During the LS diet, RPF between the races was comparable. RPF increased significantly in whites when changing from LS to HS diets (+52±14 mL/min per 1.73 m2; P=0.05). Despite similar PRA, blacks did not show the same RPF response to a change to HS diet (586±21 to 575±21 mL/min per 1.73 m2;
-10.7±17.5 mL/min per 1.73 m2; Figure).
|
|
There were no differences in GFR between the 2 groups on either diet (Table 3). The GFR increased when changing from an LS state to the HS state but did not reach significance in either group. There were also no significant differences in filtration fraction (FF) between the 2 groups for both diets, although it trended higher in blacks on the HS diet.
The subset of 11 blacks (age, 29±4.4 years) and 12 whites (age, 32±4.5 years) continued on the LS diet to receive Ang II infusions and captopril. At baseline, both groups had comparable RPF (564±29 versus 570±22 mL/min per 1.73 m2; blacks versus whites). After receiving 3 ng/kg per minute of Ang II for 45 minutes, both groups had a similarly significant decrease in renal perfusion (-104±12 versus -82±8 mL/min per m2; blacks (P=0.01) versus whites [P=0.009]). Likewise, captopril gave a similarly significant vasodilator response (564±29 to 643±30 mL/min per 1.73 m2 in blacks; P=0.002 versus 570±22 to 657±37 mL/min per 1.73 m2 in whites; P=0.003).
The Ang II infusion caused a significant elevation in both systolic and diastolic blood pressure in the 2 groups from baseline (11.4±2.7/6.9±1.4 in whites, P=0.002 versus 15.5±3.4/7.9±1.6 in blacks, P=0.003); however, the changes were not different in comparing the 2 groups of subjects. Likewise, captopril caused a significant decrease in both systolic (-5.9±1.4, P=0.003) and diastolic (-7.7±1.2, P<0.0001) pressure in blacks and caused a marginal decrement in systolic (-3±1.6, P=0.09) and significant decrement in diastolic (-6.1±1.5, P=0.003) pressure in whites. The blood pressure change between the 2 groups was not different.
| Discussion |
|---|
|
|
|---|
The simplest interpretation of this series of observations is that in blacks, the intrarenal RAS is not suppressed as effectively as in whites in response to an HS intake, but blacks show the same level of activation on an LS intake. Blacks in balance on an LS diet show a renal vascular response to renin and ACE inhibition identically to whites.10 An essentially identical construct has been presented for whites with a number of diseases, including essential hypertension in a syndrome called "nonmodulation" and in patients with type 1 and type 2 diabetes mellitus.57,8,11 In each case, evidence suggesting activation of the intrarenal RAS has gradually accumulated along with evidence that the activation contributes to disease pathogenesis.
Multiple observations have suggested that blacks differ from whites in a number of relevant ways including a blunting of sodium excretion in response to sodium loads.12,13 Other than the 24-hour sodium excretion on the initial study day, the index we have of the influence of the change in salt intake on salt balance is reflected in body weight. Although there was insufficient power for a statistical difference, the increase in body weight in the blacks exceeded that in the whites by 0.5 kg.
In a previous study comparing, renal hemodynamics and salt sensitivity in hypertensive subjects, substantial racial differences were noted.14 The salt-sensitive (SS) subjects were largely black and the salt-resistant (SR) subjects were all white. When studied during LS balance, the SS and SR patients had similar mean arterial pressure, GFR, effective renal plasma flow (ERPF), and FF. However, during studies while in HS balance, several differences were observed: ERPF increased in the SR subjects (455±25 to 524±28 mL/min, P<0.01) yet decreased in the SS subjects (538±20 to 426±16 mL/min, P<0.01); GFR did not change in either group, therefore causing the FF to decrease in the SR subjects and increase in the SS subjects.14 The authors concluded that the renal hemodynamic abnormality that was displayed while on HS balance might partially be responsible for the high rate of kidney failure in hypertensive blacks. As the renal hemodynamic pattern that Campese et al14 noted is similar in our nonhypertensive, healthy blacks, these abnormalities cannot be related to hypertension per se or to salt sensitivity because our healthy subjects were SS yet normotensive. Perhaps the differences are related to underlying physiological differences in the kidneys of these 2 racial groups.
Why should ethnicity influence a fundamental mechanism in such a powerful way? We speculate on a role for specific genetic polymorphisms. Hopkins et al15 showed in healthy whites that threonine in place of methionine at Angiotensinogen Codon-235 influences the renal vascular response to Ang II. The frequency of this polymorphism of the AGT gene is much greater in blacks than whites.16
What influences other than genetics may play a role in the lower RPF that we find in blacks? A lower potassium intake has been described in blacks.17 We found that although serum potassium was comparable in the 2 groups, 24-hour urinary potassium excretion was significantly lower in blacks.1 This trend is seen in the current study, but only on HS intake. The 24-hour urine potassium levels were similar in the 2 populations on an LS diet. Once blacks were in HS balance, the urine potassium was decreased compared not only with the LS study day but also compared with urinary potassium excretion of the whites in HS balance. Potassium intake was controlled at the same high level in both groups at each level of sodium intake. We initially believed the time period of 2 days was not long enough to replete a total body potassium deficiency, which was perhaps reflected in the lower urinary potassium excretions of the blacks. However, this difference is now seen only on the HS diet, in which the renal perfusion differences are also noted. Since the HS and LS studies were only 1 to 2 weeks apart, a decrease in dietary potassium in the blacks is unlikely to account for the difference.
We have shown the inability to increase the renal plasma flow with a high sodium intake in healthy blacksin the presence of a PRA level that is identical to whitessuggesting incomplete suppression of the renin system in the kidneys of blacks. The differences in RPF was corrected with a small dose of captopril to equal the RPF in whites, inferring that the RAS may be playing a role. This activation of the RAS, leading to a more vasoconstricted kidney, could make it more susceptible to injury. Although medication used to block the RAS has not traditionally been found to be beneficial in regard to blood pressure treatment in blacks,18,19 there may be a role for its use in the treatment of vasoconstriction in an otherwise healthy kidney.
| Acknowledgments |
|---|
Received February 18, 2002; first decision March 12, 2002; accepted May 21, 2002.
| References |
|---|
|
|
|---|
2. Hollenberg NK, Moore T, Shoback D, Redgrave J, Rabinowe S, Williams GH. Abnormal renal sodium handling in essential hypertension: relation to failure of renal and adrenal modulation of responses to angiotensin II. Am J Med. 1986; 81: 412418.[CrossRef][Medline] [Order article via Infotrieve]
3. Rabinowe SL, Redgrave JE, Shoback DM, Podolsky S, Hollenberg NK, Williams GH. Renin suppression by saline is blunted in nonmodulating essential hypertension. Hypertension. 1987; 10: 404408.
4. Fisher NDL, Price DA, Litchfield WR, Williams GH, Hollenberg NK. Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int. 1999; 56: 635641.[CrossRef][Medline] [Order article via Infotrieve]
5. DeOliveira JM, Price DA, Fisher NDL, Allen DR, McKnight JA, Williams GH, Hollenberg NK. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int. 1997; 52: 771777.[Medline] [Order article via Infotrieve]
6. Price DA, DeOliveira Fisher NDL, Williams GH, Hollenberg NK. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens. 1999; 12: 348355.[Medline] [Order article via Infotrieve]
7. Hollenberg NK, Williams GH. Abnormal renal function: Na-volume homeostasis, and renin system behavior in normal-renin essential hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven; 1999: 13491370.
8. Price DA, Porter LE, Gordon M, Fisher NDL, DeOliveira JMF, Laffel LMB, Passan DR, Williams GH, Hollenberg NK. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999; 10: 23822391.
9. Emanuel RL, Cain JP, Williams GH. Double antibody radioimmunoassay of renin activity and angiotensin II in human peripheral plasma. J Lab Clin Med. 1973; 81: 632640.[Medline] [Order article via Infotrieve]
10. Fisher NDL, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK. Responses to converting enzyme and renin inhibition: role of angiontensin II in humans. Hypertension. 1994; 23: 4451.
11. Lansang MC, Price DA, Laffel LMB, Osei SY, Fisher NDL, Erani D, Hollenberg NK. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int. 2001; 59: 14321438.[CrossRef][Medline] [Order article via Infotrieve]
12. Barlow RJ, Connell MA, Levendig BJ, Gear JS, Milne FJ. A comparative study of urinary sodium and potassium excretion in normotensive urban black and white South African males. S Afr Med J. 1982; 62: 939941.[Medline] [Order article via Infotrieve]
13. Luft FC, Grim CE, Fineberg N, Weinberger MC. Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation. 1979; 59: 643650.
14. Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension. 1991; 18: 805812.
15. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin MC, Skuppin J, Williams CS, Dluhy RG, Lalouel JM, Williams RR, Williams GH. Blunted renal vascular response to Ang II is associated with a common variant of the AGT gene and obesity. J Hypertens. 1996; 14: 199207.[CrossRef][Medline] [Order article via Infotrieve]
16. Rotimi C, Puras A, Cooper R, McFarlane-Anderson N, Forrester T, Ogunbiyi O, Morrison L, Ward R. Polymorphisms of renin-angiotensin genes among Nigerians, Jamaicans, and African Americans. Hypertension. 1996; 27: 558563.
17. Aderounmu AF. The relative importance of genetic and environmental factors in hypertension in black subjects. Clin Exp Hypertens. 1996; 3: 597621.
18. Saunders E. Hypertension in blacks. Med Clin North Am. 1987; 71: 10131029.[Medline] [Order article via Infotrieve]
19. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Frye C, Lakshman R, Gottdiener J. Single-drug therapy for hypertension in men: a comparison of 6 antihypertensive agents with placebo. N Engl J Med. 1993; 328: 914921.
This article has been cited by other articles:
![]() |
M. Azizi, J. Menard, A. Bissery, T.-T. Guyene, and A. Bura-Riviere Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 947 - 955. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Liu, J. L. Garvin, Y. Ren, P. J. Pagano, and O. A. Carretero Depolarization of the macula densa induces superoxide production via NAD(P)H oxidase Am J Physiol Renal Physiol, June 1, 2007; 292(6): F1867 - F1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. H. van den Born, U. P.F. Honnebier, R. P. Koopmans, and G. A. van Montfrans Microangiopathic Hemolysis and Renal Failure in Malignant Hypertension Hypertension, February 1, 2005; 45(2): 246 - 251. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Weinberger More on the Sodium Saga Hypertension, November 1, 2004; 44(5): 609 - 611. [Full Text] [PDF] |
||||
![]() |
V. M. Vehaskari, T. Stewart, D. Lafont, C. Soyez, D. Seth, and J. Manning Kidney angiotensin and angiotensin receptor expression in prenatally programmed hypertension Am J Physiol Renal Physiol, August 1, 2004; 287(2): F262 - F267. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Jones Dietary Sodium and Blood Pressure Hypertension, May 1, 2004; 43(5): 932 - 935. [Full Text] [PDF] |
||||
![]() |
A. Aviv, N. K. Hollenberg, and A. Weder Urinary Potassium Excretion and Sodium Sensitivity in Blacks Hypertension, April 1, 2004; 43(4): 707 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Materson High Blood Pressure in African Americans Arch Intern Med, March 10, 2003; 163(5): 521 - 522. [Full Text] [PDF] |
||||
![]() |
H. Kobori, A. Nishiyama, Y. Abe, and L. G. Navar Enhancement of Intrarenal Angiotensinogen in Dahl Salt-Sensitive Rats on High Salt Diet Hypertension, March 1, 2003; 41(3): 592 - 597. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |